Keywords: gsk, who-tdr, medicines, malaria, venture, act, accord
GSK, WHO-TDR, Medicines for Malaria Venture in ACT accord
Article | 03 May 2004
GlaxoSmithKline, the World Health Organization's Special Programme for Research and Training in Tropical Diseases (WHO-TDR) and the Medicines for Malaria ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
